UK markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
14.26+0.14 (+0.96%)
As of 01:53PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close14.12
Bid14.24 x 4000
Ask14.25 x 900
Day's range14.15 - 14.26
52-week range13.05 - 17.31
Avg. volume2,631,875
Market cap44.268B
Beta (5Y monthly)0.80
PE ratio (TTM)30.33
EPS (TTM)0.47
Earnings dateN/A
Forward dividend & yield0.80 (5.65%)
Ex-dividend date29 Sept 2021
1y target est21.02
  • Zacks

    TAK vs. ZTS: Which Stock Should Value Investors Buy Now?

    TAK vs. ZTS: Which Stock Is the Better Value Option?

  • Zacks

    Wall Street Analysts See a 26% Upside in Takeda Pharmaceutical Co. (TAK): Can the Stock Really Move This High?

    The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • Reuters

    Takeda maintains annual guidance despite first-quarter profit drop

    TOKYO (Reuters) -Japan's biggest drugmaker Takeda Pharmaceutical Co reported a sharp drop in first-quarter profit on Thursday, reflecting one-off gains a year earlier, while maintaining annual earnings forecasts that are buoyed by the yen's decline. In the first quarter of last fiscal year, Takeda benefited from a one-time gain of 131.4 billion yen when it sold off its diabetes assets to refocus on core businesses following its acquisition of Shire Plc. The next major driver for Takeda's earnings and shares may be a decision by European regulators, expected later this year, on the company's experimental vaccine for Dengue fever.